Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for various diseases. With a market cap of $132.4 billion, Regeneron’s operations span various countries in North America, Europe, and Asia.

Shares of the biotech giant have substantially outperformed the broader market over the past year. Over the past 52 weeks, REGN stock notably gained 44.7%, outpacing the S&P 500 Index’s ($SPX) 27.7% returns. In 2024, REGN is up 36.8% compared to SPX’s nearly 18% gains on a YTD basis.

Narrowing the focus, REGN has outpaced the Nasdaq Biotechnology Ishares ETF’s (IBB) 15.9% returns over the past 52 weeks and 8.9% gains on a YTD basis.

www.barchart.com

Shares of Regeneron rose 1.3% after the release of its stronger-than-expected Q2 earnings on Aug. 1, driven by robust sales of its eczema and eye treatments. The company’s revenue grew 12.3% annually to $3.55 billion due to significant sales growth in Libtayo, Praluent, and Evkeeza. The company also reported a 10.5% increase in R&D investment to $1.2 billion, highlighting its commitment to innovation.

For the current fiscal year, ending in December, analysts expect Regeneron’s EPS to grow marginally compared to the previous year, reaching $37.80. The company’s earnings surprise history is mixed. It surpassed the consensus estimates in three of the past four quarters while missing on another occasion. Its EPS for the last reported quarter surpassed the consensus estimates by 13.1% to $10.10.

Among the 26 analysts covering the REGN stock, the consensus rating is a “Strong Buy.” That’s based on 19 “Strong Buy” ratings, one “Moderate Buy,” five “Holds,” and one “Moderate Sell.”

www.barchart.com

This configuration has been consistent over the past months.

On Aug. 23, Piper Sandler analyst Christopher Raymond maintained a “Buy” rating on REGN, with a price target of $1,242.

While REGN is currently trading above its mean price target of $1,164.74, the Street-high target of $1,300 represents a potential upside of 8.2% from current price levels.

More Stock Market News from Barchart

• Booking Holdings Stock: Is Wall Street Bullish or Bearish?
• 1 Dividend Aristocrat to Buy Now and Hold for Long-Term Gains
• What Are Wall Street Analysts’ Target Price for Garmin Stock?
• Do Wall Street Analysts Like Discover Financial Stock?

On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.